KMO is a novel prognostic marker or oncogenic protein in human hepatocellular carcinoma [38] and triple-negative breast cancer [39, 40], suggesting that it is a promotor for tumour progression. This evidence concerns the gene KMO and triple-negative breast carcinoma.